8 results for "Harry Comber"
Showing 1–8 · 0.31 seconds · RSS
-
Journal Article Full text
Socioeconomic Disparity in Survival after Breast Cancer in Ireland: Observational Study
We evaluated the relationship between breast cancer survival and deprivation using data from the Irish National Cancer Registry. Cause-specific survival was compared between five area-based socioeconomic deprivation strata using Cox regression. Patient and tumour characteristics and treatment were…
Also available at: DOAJ
-
Journal Article Full text
Affluence and Private Health Insurance Influence Treatment and Survival in Non-Hodgkin’s Lymphoma
Background: The aim of this study was to investigate inequalities in survival for non-Hodgkin’s lymphoma (NHL), distinguishing between direct and indirect effects of patient, social and process-of-care factors. Methods: All cases of NHL diagnosed in Ireland in 2004–2008 were included. Variables…
Also available at: DOAJ
-
Journal Article
Mechanisms and mediation in survival analysis: towards an integrated analytical framework
Abstract Background A wide-ranging debate has taken place in recent years on mediation analysis and causal modelling, raising profound theoretical, philosophical and methodological questions. The authors build on the results of these discussions to work towards an integrated approach to the…
-
Journal Article
Uncertainty and Quality of Life Among Men Undergoing Active Surveillance for Prostate Cancer in the United States and Ireland
Background . Prostate cancer continues to be the most common site of male cancers, particularly among older men in Europe and the United States, and the second most common male cancer worldwide. Active surveillance involves the use of no local or systemic therapy once prostate cancer has been…
-
Journal Article Full text
Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Background: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of pravastatin, demonstrated a 19% reduction in coronary outcomes (p = 0.006) after a mean of 3.2 years, with no impact on stroke outcomes or all-cause mortality. However, there was a…
Also available at: DOAJ